DaVita (NYSE:DVA) Hits New 1-Year High – Should You Buy?

DaVita Inc. (NYSE:DVA) reached a new 52-week high on Monday . The stock traded as high as $179.60 and last traded at $175.61, with a volume of 508351 shares trading hands. The stock had previously closed at $176.50.

Analyst Ratings Changes

Separately, Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average target price of $161.80.

DaVita Stock Performance

The firm has a market capitalization of $14.55 billion, a PE ratio of 19.14, a P/E/G ratio of 0.86 and a beta of 0.93. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The business has a 50-day simple moving average of $160.10 and a 200-day simple moving average of $155.85.

Institutional Investors Weigh In On DaVita

Institutional investors have recently made changes to their positions in the company. Transcendent Capital Group LLC purchased a new stake in DaVita in the 3rd quarter worth about $25,000. Blue Trust Inc. raised its holdings in shares of DaVita by 56.4% in the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after buying an additional 119 shares during the period. Quarry LP bought a new stake in shares of DaVita during the 3rd quarter worth approximately $60,000. Venturi Wealth Management LLC grew its position in DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock valued at $61,000 after acquiring an additional 152 shares during the last quarter. Finally, Versant Capital Management Inc increased its stake in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after purchasing an additional 169 shares during the period. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.